HIV/AIDS – Page 2

Efficacy of Bictegravir-Based Regimen vs. Ritonavir-Boosted Protease Inhibitors in HIV Patients on Second-Line Therapy in Haiti: Insights from a Randomized Non-Inferiority Trial

By MedXY 09/21/2025

A randomized trial in Haiti demonstrates that switching to bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to ritonavir-boosted protease inhibitors in maintaining viral suppression among second-line HIV therapy patients.

HIV/AIDS news Nursing & care Pediatrics Specialties

Bridging Pediatric and Adult HIV Care: Evaluating Outcomes and Perspectives from a Novel Transition Clinic for Young People Living with HIV

By MedXY 08/16/2025

This mixed-methods study assesses a novel Adolescent and Young Adult Healthcare Transition (AYA HCT) clinic that achieved high retention but suboptimal viral suppression among youth with HIV, highlighting key strengths and barriers.

AI HIV/AIDS news Specialties

Assessing an AI Chatbot for HIV Prevention in Malaysia: Insights and Usability

By MedXY 08/11/2025

An observational study evaluates an AI chatbot's usability in promoting HIV testing among men who have sex with men in Malaysia, showcasing potential improvements for public health interventions.

Clinical Updates HIV/AIDS Infectious Diseases news Specialties

M72/AS01E-4 Tuberculosis Vaccine: Promising Advances for HIV-Positive Populations in High-Burden Settings

By MedXY 08/05/2025

A phase 2 trial in South Africa shows that the M72/AS01E-4 TB vaccine is safe and immunogenic for virally suppressed, ART-treated HIV-positive adolescents and adults, supporting its potential to address a key unmet clinical need.

Clinical Updates HIV/AIDS news Specialties

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

By MedXY 08/03/2025

The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.

Clinical Updates HIV/AIDS news Specialties Urology

Doxycycline Post-Exposure Prophylaxis Significantly Reduces Bacterial STIs Among MSM and Transgender Women: Final Results from the DoxyPEP Trial

By MedXY 08/02/2025

The DoxyPEP trial demonstrates that doxycycline post-exposure prophylaxis markedly lowers bacterial STI incidence in men who have sex with men and transgender women, with good tolerability and minimal resistance over 12 months.

Clinical Updates HIV/AIDS news Specialties

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial

By MedXY 08/02/2025

TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.

HIV/AIDS Medical News news Public Health Specialties

FDA Approves Lenacapavir: A Twice-Yearly Injectable PrEP Transforming HIV Prevention

By MedXY 07/31/2025

Lenacapavir (Yeztugo) becomes the first FDA-approved, twice-yearly injectable PrEP, offering robust long-acting HIV prevention and addressing key adherence barriers.

Clinical Updates HIV/AIDS news Specialties

Novel HIV Peptides Identified During Treatment Interruption May Inform Next-Generation Therapeutic Strategies

By MedXY 07/30/2025

Discovery of genetically conserved, mutation-intolerant HIV peptides in rebound virus during analytic treatment interruption highlights new avenues for mRNA vaccine development and functional HIV cure strategies.

HIV/AIDS news Specialties

Assessing Antibiotic Use During Pregnancy: Impact on Birth Outcomes in HIV Contexts

By MedXY 07/29/2025

A clinical study reveals that trimethoprim-sulfamethoxazole does not significantly improve infant birth weight or related outcomes in HIV-positive pregnancies.